carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['durva', ' bev ', 'duo-o']
duo-o: primary endpoint: pfs in bev-ola-durva vs bev in hrd+ pts!!!! i really wonder how it was accepted by authorities. a certain winner. co-primary the same in itt!!!! hrp patients should be tested. however this analysis is missing in the predefined statistical plan. #asco23 
Ασυνάρτητος και ημιτελής. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.